Arrowhead Research Corp. (ARWR) Shares Up 2.9%
Arrowhead Research Corp. (NASDAQ:ARWR) shot up 2.9% during trading on Friday . The company traded as high as $5.75 and last traded at $5.74, with a volume of 108,336 shares trading hands. The stock had previously closed at $5.58.
A number of research firms have commented on ARWR. Chardan Capital began coverage on Arrowhead Research Corp. in a research note on Thursday, May 19th. They issued a “buy” rating and a $12.00 price target for the company. Jefferies Group reiterated a “hold” rating and issued a $4.75 price target on shares of Arrowhead Research Corp. in a research note on Wednesday, May 11th. Finally, Vetr upgraded Arrowhead Research Corp. from a “hold” rating to a “strong-buy” rating and set a $7.88 price target for the company in a research note on Wednesday, April 20th. Two equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $10.27.
The firm’s market capitalization is $338.77 million. The company’s 50 day moving average price is $5.73 and its 200-day moving average price is $5.05.
Arrowhead Research Corp. (NASDAQ:ARWR) last posted its earnings results on Tuesday, May 10th. The company reported ($0.35) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.02. On average, equities analysts predict that Arrowhead Research Corp. will post ($1.40) EPS for the current year.
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.